Novo Nordisk Secures Dual EU Backing for Wegovy as Semaglutide Liver Data Strengthens Pipeline
Novo Nordisk gains CHMP backing for Wegovy 7.2mg pen and oral tablet, presents promising MASH data, and announces…
Oral Wegovy Wins EMA Panel Backing, Yet Novo Nordisk Shares Remain Under Pressure
EMA recommends first oral GLP-1 obesity pill for EU approval, but Novo Nordisk shares tumble 15% YTD amid…